EUVIMEDEUVIMED entdecken
Crossref

Macrophage SHP2 Deficiency Alleviates Diabetic Nephropathy via Suppression of MAPK/NF-κB– Dependent Inflammation

Xue Han, Jiajia Wei, Ruyi Zheng, Yu Tu, Mengyang Wang, Lingfeng Chen, Zheng Xu, Lei Zheng, Chao Zheng iD, Qiaojuan Shi, Huazhong Ying, Guang Liang iD

Diabetes · 2024

DOI: 10.2337/db23-0700 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, 2024. Verfasst von Xue Han und 11 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Provincial Key Laboratory of Laboratory Animals and Safety Research, Hangzhou Medical College, Hangzhou, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Experimental, Diabetic Nephropathies, Protein Tyrosine Phosphatase, Non-Receptor Type 11. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province, Zhejiang Provincial Key Scientific Project, Zhejiang Provincial Medicine and Health Science and Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increasing evidence implicates chronic inflammation as the main pathological cause of diabetic nephropathy (DN). Exploration of key targets in the inflammatory pathway may provide new treatment options for DN. We aimed to investigate the role of Src homology 2–containing protein tyrosine phosphatase 2 (SHP2) in macrophages and its association with DN. The upregulated phosphorylation of SHP2 was detected in macrophages in both patients with diabetes and in a mouse model. Using macrophage-specific SHP2-knockout (SHP2-MKO) mice and SHP2fl/fl mice injected with streptozotocin (STZ), we showed that SHP2-MKO significantly attenuated renal dysfunction, collagen deposition, fibrosis, and inflammatory response in mice with STZ-induced diabetes. RNA-sequencing analysis using primary mouse peritoneal macrophages (MPMs) showed that SHP2 deletion mainly affected mitogen-activated protein kinase (MAPK) and nuclear factor-κB (NF-κB) signaling pathways as well as MAPK/NF-κB–dependent inflammatory cytokine release in MPMs. Further study indicated that SHP2-deficient macrophages failed to release cytokines that induce phenotypic transition and fibrosis in renal cells. Administration with a pharmacological SHP2 inhibitor, SHP099, remarkably protected kidneys in both type 1 and type 2 diabetic mice. In conclusion, these results identify macrophage SHP2 as a new accelerator of DN and suggest that SHP2 inhibition may be a therapeutic option for patients with DN. Article Highlights

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, ExperimentalDiabetic NephropathiesProtein Tyrosine Phosphatase, Non-Receptor Type 11AnimalsHumansMiceCytokinesFibrosisInflammationMacrophagesMice, KnockoutMitogen-Activated Protein KinasesNF-kappa B

Substanzen

CytokinesMitogen-Activated Protein KinasesNF-kappa BPtpn11 protein, mousePTPN11 protein, humanProtein Tyrosine Phosphatase, Non-Receptor Type 11

Autor:innen und Institutionen

  • Zhejiang Provincial Key Laboratory of Laboratory Animals and Safety Research, Hangzhou Medical College, Hangzhou, China.
  • Zhejiang Traditional Chinese Medicine Key Laboratory of Pharmacology and Translational Research of Natural Products, School of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, China.
  • Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
  • Department of Pharmacology, College of Pharmacy, Beihua University, Jilin, China.
  • Department of Endocrinology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

ORCID-Profile: Chao Zheng, Guang Liang

Förderung

  • Natural Science Foundation of Zhejiang Province
  • Zhejiang Provincial Key Scientific Project
  • Zhejiang Provincial Medicine and Health Science and Technology Project

Zitieren

APA

Han, X., Wei, J., Zheng, R., Tu, Y., Wang, M., Chen, L., Xu, Z., Zheng, L., Zheng, C., Shi, Q., Ying, H., & Liang, G. (2024). Macrophage SHP2 Deficiency Alleviates Diabetic Nephropathy via Suppression of MAPK/NF-κB– Dependent Inflammation. Diabetes. https://doi.org/10.2337/db23-0700

Vancouver

Han X, Wei J, Zheng R, Tu Y, Wang M, Chen L, et al. Macrophage SHP2 Deficiency Alleviates Diabetic Nephropathy via Suppression of MAPK/NF-κB– Dependent Inflammation. Diabetes. 2024. doi:10.2337/db23-0700

BibTeX
@article{Han2024,
  author = {Han, Xue and Wei, Jiajia and Zheng, Ruyi and Tu, Yu and Wang, Mengyang and Chen, Lingfeng and Xu, Zheng and Zheng, Lei and Zheng, Chao and Shi, Qiaojuan and Ying, Huazhong and Liang, Guang},
  title = {Macrophage SHP2 Deficiency Alleviates Diabetic Nephropathy via Suppression of MAPK/NF-κB– Dependent Inflammation},
  journal = {Diabetes},
  year = {2024},
  doi = {10.2337/db23-0700}
}
Kostenlos starten →